QPPV.COM KNOWLEDGE ASSESSMENT

EU Marketing Authorisation Procedures: Professional Knowledge Assessment

Test your understanding of the concepts covered by Centralised, National, Mutual Recognition and Decentralised Procedures Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal context for an Article 30 referral as described in the article?

Simultaneous first authorisation of a medicine in several Member States Disagreement between an RMS and CMS during a DCP only Divergent national decisions or the need to promote harmonisation of national authorisations in the defined legal context Routine translation of product information after a centralised authorisation

Question 2 of 10 Why is it insufficient for a pharmacovigilance system to record only that an active substance is 'authorised in Europe'?

Active substances cannot be associated with medicinal products The phrase does not identify the specific products, authorisations, Member States, MAHs or procedural route relevant to regulatory action European authorisations do not require product information Only centrally authorised substances can be monitored

Question 3 of 10 Which statement best distinguishes an MRP/DCP disagreement from a later post-authorisation referral?

They are always the same procedure because both involve nationally authorised medicines An MRP/DCP disagreement arises during the authorisation procedure, whereas a later safety issue may invoke a different post-authorisation legal mechanism A later referral can occur only before any marketing authorisation exists Article 29 is exclusively a pharmacovigilance procedure and cannot concern product information

Question 4 of 10 What is the principal regulatory outcome when an MRP or DCP concludes with agreement?

One European Commission decision covering every Member State Multiple national marketing authorisations based on a coordinated European assessment A CHMP opinion that has no national implementation A single national authorisation held by the RMS on behalf of the CMSs

Question 5 of 10 What is the role of CMDh during the relevant Article 29 disagreement stage?

To seek agreement among the Member States within the applicable coordination period To grant the final Union marketing authorisation To replace PRAC for all pharmacovigilance assessments To determine commercial pricing in each Member State

Question 6 of 10 Which sequence best represents the centralised procedure for a human medicine?

National competent authority assessment, CMDh agreement, national authorisations EMA submission, CHMP scientific opinion, European Commission legally binding decision RMS assessment, CMS review, national decisions without EU involvement PRAC opinion, national authority decision, European Commission endorsement

Question 7 of 10 What is the essential difference between MRP and DCP?

MRP involves EMA, whereas DCP never involves national authorities MRP begins with an existing national authorisation, whereas DCP begins without an existing EU national authorisation MRP produces a Union authorisation, whereas DCP produces a scientific opinion MRP is limited to safety issues, whereas DCP is limited to efficacy issues

Question 8 of 10 An MAH identifies a serious potential safety signal for a product authorised through DCP in eight Member States. What should be established first when planning regulatory escalation?

Whether the product can be treated as centrally authorised because the signal is serious The product-level regulatory footprint, including the authorisation route, RMS, CMSs and affected Member States Whether the RMS can independently change all national product information Whether the active substance has ever been used anywhere in the EU

Question 9 of 10 Which statement correctly describes national competent authorities after a centralised marketing authorisation has been granted?

They have no further role because the European Commission has authorised the product They may retain responsibilities such as inspections, pharmacovigilance, supervision and enforcement They become CMSs automatically They replace CHMP for the central scientific assessment

Question 10 of 10 A regulatory professional sees RMS, CMS, CMDh and a procedure number in a document. What is the most reasonable first-pass interpretation?

The document most likely concerns an MRP or DCP product The document must concern a centrally authorised product The document is necessarily a national-only procedure with no European coordination The document is necessarily an inspection report rather than an authorisation document

QPPV.com

EU Marketing Authorisation Procedures: Professional Knowledge Assessment

Cookie Settings